✨ Free AI Report
Agenus Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Agenus Inc.
Company Research

Agenus Inc.: Business Overview, Financials & Competitive Analysis

Agenus Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage biotech with high-risk/high-reward profile dependent on botensilimab/balstilimab combination and checkpoint modulator candidates, trading at significant discount despite strategic partnerships. Agenus has strong partnerships and a diversified pipeline in high-value oncology markets, but faces clinical and regulatory challenges. The stock reached its all-time low of 1.38 USD in April 2025.

What is Agenus Inc.'s industry? Agenus Inc. (agenusbio.com) operates in Biotechnology - Immuno-Oncology. AskCyborg classifies Agenus Inc. under Biotechnology - Immuno-Oncology in its company registry.

Agenus is a clinical-stage biotechnology company that discovers and develops therapies to activate the body's immune system against cancer and infections. The company operates a comprehensive immuno-oncology pipeline ...

4/ 10Mixed

Cyborg Score thesis

Clinical-stage biotech with high-risk/high-reward profile dependent on botensilimab/balstilimab combination and checkpoint...

Read the full analyst-debate transcript →
Industry Biotechnology - Immuno-Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Agenus Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Agenus Inc.

AskCyborg analysts argue the bull and bear cases for Agenus Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Agenus Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Agenus Inc. Overview

Pro stress-test →

Agenus is a clinical-stage biotechnology company that discovers and develops therapies to activate the body's immune system against cancer and infections. The company operates a comprehensive immuno-oncology pipeline with collaborations with Bristol-Myers Squibb, Gilead Sciences, Incyte Corporation, and Merck Sharp & Dohme.

Strategic Profile

Pro stress-test →

The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. In 2025, Agenus sold their CDMO business to Zydus Lifesciences and partnered with Zydus to commercialize their molecules in India.

Competitive Landscape

Pro stress-test →

Agenus competes in immuno-oncology with major players including Bristol-Myers Squibb, Merck, Incyte, and Gilead across checkpoint inhibitors and adoptive cell therapies. The company differentiates through its Retrocyte Display antibody platform, QS-21 Stimulon adjuvant, and Prophage personalized cancer vaccines. Partnerships amplify reach rather than direct competition.

Industry Context

Agenus Inc. operates in Biotechnology - Immuno-Oncology.

Key facts

Founded: 1994 · Headquarters: Lexington, Massachusetts · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Agenus Inc..

  • In August 2023, the company underwent strategic restructuring with a 25% workforce reduction and suspension of most non-BOT/BAL programs, intended to reduce annual operating expenses by approximately $40 million
  • Agenus is the sole US-manufacturer of QS-21, a key component in Oxford-AstraZeneca and Novavax COVID-19 vaccines, with supplies tightly controlled under the US Defence Production Act
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Closed strategic collaboration with Zydus Lifesciences for CDMO asset sale and India commercialization
  • 2025Divested CDMO business including manufacturing sites in Emeryville and Berkeley
  • +1 moreTrack every material event for Agenus Inc. as it happens. Explore monitoring →
Get alerted when Agenus Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Checkpoint inhibitorsMajor pharma developing competing PD-1, CTLA-4, and other checkpoint modulator therapies→CAR-T and cell therapiesAdoptive cell therapy competitors to MiNK Therapeutics platform→Cancer vaccine platformsCompeting personalized and off-the-shelf cancer vaccine approaches→

Compare Agenus Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Agenus Inc. operates in Biotechnology - Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about Agenus Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Agenus Inc. and its top competitor on Cyborg Score”
“What did Agenus Inc. do this quarter?”
“Is Agenus Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Agenus Inc. do?+
Agenus is a clinical-stage biotechnology company that discovers and develops therapies to activate the body's immune system against cancer and infections. The company operates a comprehensive immuno-oncology pipeline ...
What is Agenus Inc.'s Cyborg Score?+
Agenus Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Agenus Inc.'s main competitors?+
Named competitors include Checkpoint inhibitors, CAR-T and cell therapies, Cancer vaccine platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Agenus Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Agenus Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Agenus Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Immuno-Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

5ALX Oncology Holdings Inc.5Merus N.V.